Accuracy of Spircare Device as Compared to the Conventional Plethysmograph
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Kfar-Saba, Israel, 4428164
- "Meir" Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Phase I Health subjects without respiratory system disease.
Phase II Subjects which are referred to a Pulmonary Functional Testing in the Meir pulmonary unit.
Description
Inclusion Criteria:
- Signed Informed consent.
- Age≥18 year.
- Subject is cooperative and capable of following instructions.
- Phase I: Healthy asymptomatic subjects, never smokers without known history of respiratory, cardiovascular, hepatic, renal or metabolic disease.
Phase II: Chronic pulmonary patients with lung volume disorders:
- COPD
- Asthma
- Restrictive diseases such as pulmonary fibrosis, other interstitial lung diseases, kyphoscoliosis, neuro-muscular disorders.
Exclusion Criteria:
- Subjects unable or unwilling to give informed consent.
- Subjects who are unable to satisfactorily perform routine, full lung function testing (due to non-compliance or claustrophobia).
- History suggesting upper respiratory infection during the four weeks prior to testing
- Physical activity during 1 hour prior to the Study.
- Patients with a tracheostomy.
- Pregnant women.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The FRC and air way resistance values of the body plethysmograph will be compared to the values of the Spircare device
Time Frame: September 2017
|
The primary outcome of the FRC and air way resistance of the Spircare device against the plethysmograph will be displayed as scatter plot.
A linear regression and the R2 value will be display as well.
The associated Bland-Altman plots comparing the FRC and airway resistance of the Spircare device to the plethysmograph with lines that represent width of 0.1 (±1.96*SD).
|
September 2017
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DA-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.